SkylineDx's Merlin CP-GEP™: A Breakthrough in Early Melanoma Metastasis Prediction SkylineDx announces promising findings on Merlin CP-GEP™, a gene expression test that enhances prediction of sentinel lymph node metastasis in early melanoma.

SkylineDx's Merlin CP-GEP™: A Breakthrough in Early Melanoma Metastasis Prediction #United_States #San_Diego #SkylineDx #melanoma #Merlin_CP-GEP

SkylineDx Introduces New Initiative for Melanoma Risk Assessment and Decision-Making SkylineDx's initiative aims to enhance SLNB decision-making in early-stage melanoma by aligning with updated NCCN guidelines to improve patient outcomes.

SkylineDx Introduces New Initiative for Melanoma Risk Assessment and Decision-Making #Netherlands #Rotterdam #SkylineDx #melanoma #CP-GEP

Innovative Merlin CP-GEP Test Boosts Melanoma Prognosis with New Findings A recent independent study in the Netherlands confirms the effectiveness of the Merlin CP-GEP Test for predicting melanoma prognosis in patients, enhancing personalized care.

Innovative Merlin CP-GEP Test Boosts Melanoma Prognosis with New Findings #Netherlands #Rotterdam #SkylineDx #Merlin_CP-GEP #Melanoma_Test

New Insights from SkylineDx Highlight Merlin CP-GEP Test's Effectiveness in Melanoma Risk Assessment Recent findings by SkylineDx suggest that the Merlin CP-GEP Test offers superior melanoma risk stratification compared to conventional methods, enhancing patient care.

New Insights from SkylineDx Highlight Merlin CP-GEP Test's Effectiveness in Melanoma Risk Assessment #Netherlands #Rotterdam #SkylineDx #melanoma #Merlin_CP-GEP_Test

SkylineDx Honored as Diagnostics Company of the Year at the 2025 BioTech Breakthrough Awards SkylineDx has been awarded 'Diagnostics Company of the Year' for its innovative genomic assays that improve cancer treatment decisions for patients and clinicians.

SkylineDx Honored as Diagnostics Company of the Year at the 2025 BioTech Breakthrough Awards #Netherlands #diagnostics #Rotterdam #SkylineDx #BioTech_Breakthrough

SkylineDx's MERLIN_001 Trial Validates Merlin CP-GEP Test for Melanoma Risk Stratification SkylineDx's MERLIN_001 trial reveals the effectiveness of the Merlin CP-GEP Test in stratifying melanoma patients by risk, aiding decision-making.

SkylineDx's MERLIN_001 Trial Validates Merlin CP-GEP Test for Melanoma Risk Stratification #USA #San_Diego #SkylineDx #melanoma #Merlin_CP-GEP

SkylineDx's Innovative Merlin Assay Significantly Reduces Sentinel Lymph Node Biopsies in Melanoma Patients SkylineDx's Merlin Assay demonstrates remarkable efficacy in reducing sentinel lymph node biopsies by over 40% in melanoma patients, enhancing treatment decision-making.

SkylineDx's Innovative Merlin Assay Significantly Reduces Sentinel Lymph Node Biopsies in Melanoma Patients #Netherlands #Rotterdam #SkylineDx #melanoma #Merlin_Assay

SkylineDx's Merlin CP-GEP Assay Shows High Predictive Accuracy for Patient Selection in Sentinel Lymph Node Biopsy A recent independent meta-analysis validates the efficacy of SkylineDx's Merlin CP-GEP assay, showing its ability to accurately assess patients' needs for sentinel lymph node biopsy in melanoma cases.

SkylineDx's Merlin CP-GEP Assay Shows High Predictive Accuracy for Patient Selection in Sentinel Lymph Node Biopsy #Netherlands #Rotterdam #SkylineDx #Merlin_Assay #CP-GEP

Groundbreaking Findings on SKY92 Revolutionize Multiple Myeloma Risk Assessment and Treatment Planning SkylineDx reveals promising results from the PROMMIS study, confirming that SKY92 gene profiling improves risk stratification in multiple myeloma patients, enhancing treatment decisions and patient care.

Groundbreaking Findings on SKY92 Revolutionize Multiple Myeloma Risk Assessment and Treatment Planning #United_States #San_Diego #Multiple_Myeloma #SkylineDx #SKY92

SkylineDx Unveils Mermaid Assay at ASCO 2025 to Revolutionize Melanoma Recurrence Predictions SkylineDx highlights the Merlin Assay's capability to predict recurrence risk in head and neck melanoma at the ASCO 2025 conference, supporting non-invasive approaches.

SkylineDx Unveils Mermaid Assay at ASCO 2025 to Revolutionize Melanoma Recurrence Predictions #Netherlands #Rotterdam #SkylineDx #melanoma #Merlin_Assay

SkylineDx Unveils Key Findings on Melanoma Risk Assessment with Merlin CP-GEP Study SkylineDx shares groundbreaking results on the Merlin CP-GEP test, advancing melanoma risk assessment by identifying high-risk patients beyond standard criteria.

SkylineDx Unveils Key Findings on Melanoma Risk Assessment with Merlin CP-GEP Study #Netherlands #Rotterdam #SkylineDx #melanoma #Merlin_CP-GEP

SkylineDx Unveils Groundbreaking Results from Landmark Melanoma GEP Trial at SSO 2025 SkylineDx showcases pivotal findings from the MERLIN_001 study at the SSO 2025, highlighting enhanced melanoma risk stratification through gene expression profiling.

SkylineDx Unveils Groundbreaking Results from Landmark Melanoma GEP Trial at SSO 2025 #United_States #San_Diego #SkylineDx #melanoma #Merlin_CP-GEP

SkylineDx's Groundbreaking Research on SKY92 Gene Test Supports Ultra-High-Risk Multiple Myeloma Identification SkylineDx announces a pivotal study on the SKY92 gene expression test, enhancing multiple myeloma patient risk identification for improved treatment.

SkylineDx's Groundbreaking Research on SKY92 Gene Test Supports Ultra-High-Risk Multiple Myeloma Identification #Netherlands #Multiple_Myeloma #Rotterdam #SkylineDx #SKY92

New PROMMIS Study Reports Breakthrough in Identifying High-Risk Multiple Myeloma Patients with SKY92 Recent findings from the PROMMIS study reveal that the SKY92 gene expression profiling classifier significantly improves the identification of high-risk multiple myeloma patients, aiding in better treatment strategies.

New PROMMIS Study Reports Breakthrough in Identifying High-Risk Multiple Myeloma Patients with SKY92 #Netherlands #Multiple_Myeloma #Rotterdam #SkylineDx #SKY92